REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced new data to be featured at the ...
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology Three models for yearly time series predictions were built: autoregressive integrated ...
Analysis of the first subset of linked SEER patient data demonstrates DecisionDx®-Melanoma testing was associated with improved overall survival rates compared to untested patients DecisionDx-Melanoma ...
Data from the SEER and MUSIC registries found a decrease in prostatectomies in those with pathologic grade group 1 prostate cancer. This shift is attributed to evidence supporting active surveillance ...
The probability of overall survival after 1, 5, and 10 years was predicted by a nomogram model, which found that worse Surveillance, Epidemiology, and End Results (SEER) stage was associated with ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BALTIMORE -- The ...
Seer, Inc. will announce Q2 2025 financial results on August 6, 2025, with a webcast at 1:30 PM PT. Seer, Inc. announced that it will release its financial results for the second quarter of 2025 on ...
REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced new data to be featured at the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback